HG
HG6.F Mayne Pharma Group Limited
- Market cap
- EUR 162M
- P/E
- 11.0x
- P/B
- 0.67x
- ROE
- 6.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is HG6.F undervalued?
Graham numberHG6.F trades 42.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mayne Pharma Group Limited fundamental analysis
No fundamental analysis for Mayne Pharma Group Limited yet.
Mayne Pharma Group Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes speci…
Full company profileMayne Pharma Group Limited financial statements
Mayne Pharma Group Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 266M | 572M | 529M | 524M | 457M | 400M | 424M | 186M | 388M | 378M |
| Gross Profit | 167M | 315M | 263M | 301M | 225M | 195M | 170M | 85.4M | 218M | 243M |
| Operating Income | 53.2M | 120M | 37.8M | 22.4M | 6.00M | 21.3M | -1.55M | -167M | -139M | 78.2M |
| EBITDA | - | 195M | -71.8M | -242M | -27.2M | -163M | -105M | -176M | -87.1M | 139M |
| Net Income | 37.4M | 88.6M | -134M | -281M | -92.8M | -208M | -263M | 117M | -174M | 24.5M |
| EPS | - | 0.06 | -0.09 | -0.18 | -0.06 | -0.12 | -0.15 | 1.41 | -2.14 | 0.30 |
| Balance Sheet | ||||||||||
| Total Assets | 1.56B | 1.91B | 1.83B | 1.64B | 1.83B | 1.46B | 1.29B | 1.25B | 1.14B | 909M |
| Total Liabilities | 1.18B | 602M | 595M | 622M | 783M | 692M | 731M | 613M | 689M | 519M |
| Shareholders' Equity | 364M | 1.30B | 1.23B | 1.01B | 1.04B | 768M | 565M | 634M | 454M | 391M |
| Cash & Short-term Investments | 47.5M | 63.0M | 87.3M | 89.0M | 138M | 98.0M | 96.7M | 92.6M | 110M | 80.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 53.5M | -15.2M | 121M | 107M | 113M | 58.9M | -7.21M | -42.7M | - | - |
| Capital Expenditure | 62.8M | 104M | 54.2M | 11.9M | 8.99M | 17.1M | 10.0M | 8.34M | 20.9M | 3.32M |
| Free Cash Flow | - | -1.10B | 27.2M | 24.7M | 52.7M | 33.8M | -19.1M | -262M | -36.2M | 10.5M |
| Ratios | ||||||||||
| ROE | 10.3% | 6.8% | -10.9% | -27.9% | -8.9% | -27.1% | -46.6% | 18.5% | -38.4% | 6.3% |
| ROA | 2.4% | 4.6% | -7.3% | -17.2% | -5.1% | -14.2% | -20.4% | 9.4% | -15.2% | 2.7% |
| Net Profit Margin | 14.0% | 15.5% | -25.3% | -53.6% | -20.3% | -52.1% | -62.1% | 63.2% | -44.9% | 6.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mayne Pharma Group Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jan 18, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 45.3M | 0.54 | 38.6% |
| 2022 | AUD 45.3M | 0.03 | - |
| 2021 | AUD 45.3M | 0.03 | - |
| 2020 | EUR 45.3M | 0.03 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:20 on Jan 18, 2023.
Who owns Mayne Pharma Group Limited
- Insiders 22.61%
- Institutions 27.27%
- Public & others 50.12%
- Shares outstanding 81.9M
- Free float 44.1M
Mayne Pharma Group Limited company profile
- Company name
- Mayne Pharma Group Limited
- Ticker
- HG6.F
- ISIN
- AU000000MYX0
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 363
- Fiscal year end
- June
- Address
- 1538 Main North Road, Salisbury South, SA, Australia, 5106
- Phone
- 61 8 8209 2666
- Website
- maynepharma.com
About Mayne Pharma Group Limited
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
Mayne Pharma Group Limited management
10- Mr. Aaron GrayChief Executive Officer
- Mr. Griffin D. BuchananChief Financial Officer
- Dr. Thomas George Duthy M.B.A., Ph.D.Manager of Investor Relations
- Ms. Kimberly Parker J.D.Executive VP & General Counsel
- Mr. Brant SchofieldExecutive Vice President of Corporate Development · born 1966
- Ms. Kate SurdezVP & Global Head of Human Resources
- Mr. Daniel MoorePresident of DistributeRx
- Dr. Frank Casty M.D.Executive VP, Global Head of R&D and Chief Medical Officer
- Mr. Tony RamyExecutive Vice President of Women's Health
- Mr. Brenton WalterFinancial Controller